Kronox Lab Sciences Ltd (KRONOX)
🎯 Key Takeaways
- Kronox Lab Sciences is undergoing a strategic transformation following the sale of a controlling stake to Indo Borax & Chemicals, resulting in a change of management control and board restructuring. The company has shifted from a promoter-led governance model to a professionally managed structure with new leadership appointments, signaling a potential pivot toward operational modernization and strategic realignment in the chemicals sector.
- Revenue grew 8.6% QoQ to ₹28 in Q1FY27.
- ⚠️ The abrupt change in ownership and management introduces execution and strategic continuity risks, particularly regarding the new leadership’s ability
- Market Cap
- ₹800
- P/E Ratio
- 27.7
- P/B Ratio
- 6.89
- ROE
- 24.6%
- ROCE
- 32.9%
- Debt/Equity
- 0.01
- Div Yield
- 0.23%
- Promoter
- 74.2%
📖 The Story
Kronox Lab Sciences is undergoing a strategic transformation following the sale of a controlling stake to Indo Borax & Chemicals, resulting in a change of management control and board restructuring. The company has shifted from a promoter-led governance model to a professionally managed structure with new leadership appointments, signaling a potential pivot toward operational modernization and strategic realignment in the chemicals sector.
📰 What's Happening
In September 2026, the company completed the sale of 64.26% of its equity to Indo Borax & Chemicals, reducing promoter holdings from 74.21% to 9.95% and transferring 64.26% voting rights, effectively ending promoter control. Concurrently, key executives including Managing Director Jogindersingh Jaswal, Executive Directors Ketan and Pritesh Ramani, and CFO Samir Gadhiya resigned. The board appointed Suresh Kalra as new Managing Director and CEO, Sunil Malhotra as Whole-time Director, and added independent directors Amit Kumar Sharma, Anuradha Maheshwari, and Dhananjay Tapasvi. Committee reconstitutions were also approved to support governance under new management.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 26 | 25 | 26 | 28 |
| Operating Profit | 8 | 8 | 9 | 9 |
| OPM % | 32.0% | 29.7% | 33.9% | 30.1% |
| Net Profit | 7 | 7 | 8 | 7 |
| EPS | ₹1.82 | ₹1.79 | ₹2.18 | ₹2.00 |
The company has demonstrated stable top-line growth, with revenue rising from ₹25 crore in December 2025 to ₹28 crore in June 2026, accompanied by improving operational efficiency, as reflected in OPM expansion from 29.7% to 33.9% over the same period. Net profit margins remain healthy, with NP increasing from ₹7 crore to ₹8 crore, and EPS rising from ₹1.79 to ₹2.18, indicating consistent profitability despite the governance transition.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance in the available filings, but the leadership transition and board reshuffle suggest a focus on stabilizing operations and enhancing governance post-restructuring. The appointment of new MD & CEO Suresh Kalra and Whole-time Director Sunil Malhotra indicates an intent to drive strategic direction under professional oversight, though no formal business or financial targets have been disclosed in the regulatory submissions.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 37 | 37 | 37 | 37 |
| Reserves | 53 | 40 | 79 | 64 |
| Borrowings | 0 | 0 | 2 | 3 |
| Total Liabilities | 99 | 85 | 128 | 113 |
| Fixed Assets | 28 | 26 | 29 | 30 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 99 | 85 | 128 | 113 |
The balance sheet shows a strong equity base of ₹37 crore with growing reserves (₹79 crore as of March 2026) and minimal debt, reflecting a conservative capital structure. Total assets have increased to ₹128 crore from ₹99 crore in March 2025, suggesting ongoing investment in operations or assets, likely tied to the new management’s strategic initiatives, while maintaining financial resilience without leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +31 |
| Investing | -28 |
| Financing | -2 |
| Net Cash Flow | +0 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 74.2% | 74.2% | 74.2% | 74.2% |
| FII | 0.0% | 0.1% | 0.1% | 0.0% |
| DII | 1.9% | 2.0% | 2.0% | 2.1% |
| Public | 21.2% | 21.1% | 21.0% | 20.8% |
| # Shareholders | 35,780 | 34,608 | 33,469 | 32,479 |
Promoter holding has sharply declined from 74.21% in Q1FY27 to 9.95% post-stake sale, with no FII or DII accumulation observed — FII ownership remains negligible at 0.04–0.08%, and DII holds a stable ~2%. The broad public shareholder base (32,479 shareholders) suggests retail dominance, but the lack of institutional interest may reflect uncertainty post-restructuring or sector-specific skepticism.
⚖️ Peer Comparison — Chemicals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| PIDILITIND | 1.50 L Cr | 56.5 | 33.4% | — | 0.01 |
| SRF | 73,336 | 33.9 | 15.6% | — | 0.36 |
| LINDEINDIA | 54,023 | 98.9 | 17.5% | — | 0.00 |
| FLUOROCHEM | 48,430 | 79.2 | 9.6% | — | 0.34 |
| NAVINFLUOR | 42,306 | 53.5 | 22.2% | — | 0.31 |
| GODREJIND | 34,967 | 29.8 | 9.2% | — | 4.57 |
| HSCL | 34,188 | 42.5 | 20.7% | — | 0.16 |
| AETHER | 22,546 | 95.6 | 13.8% | — | 0.08 |
| DEEPAKNTR | 20,882 | 26.6 | 15.3% | — | 0.26 |
| CASTROLIND | 19,817 | 18.7 | 76.2% | — | 0.00 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
The abrupt change in ownership and management introduces execution and strategic continuity risks, particularly regarding the new leadership’s ability to maintain operational momentum. Additionally, the company’s heavy reliance on a single segment or customer base is not disclosed, but the lack of transparency post-restructuring could hinder investor confidence. Regulatory and compliance risks may also increase during the transition phase.
📋 Recent Filings
- 🔴 Insider Trading2026-10-01Kronox Lab Sciences disclosed three insider sales on October 1, 2026 under SEBI PIT Regulation 7(2). Mr. Jogindersingh Jaswal sold 9,796,400 shares (~…
- 🔴 Insider Trading2026-09-30Kronox Lab Sciences disclosed an insider transaction where Jogindersingh Gianchand Jaswal sold 85,66,400 shares representing 23.088% of the company's …
- 🔴 Announcement2026-09-29Kronox Lab Sciences announced the resignation of its CFO Samir Gadhiya effective September 29, 2026, alongside a major board reshuffle following the s…
- Announcement2026-09-29Kronox Lab Sciences Ltd announced that its trading window for insider transactions will close on October 1, 2026, ahead of the board's announcement of…
- 🔴 Announcement2026-09-29Kronox Lab Sciences announced the completion of a share sale that transferred 64.26% of its equity to a buyer, reducing promoter holdings to 9.95%. Th…
- 🟡 Board Meeting2026-09-29Kronox Lab Sciences announced the completion of a 64.26% share sale to Indo Borax & Chemicals, reducing promoter holdings to 9.95% and triggering boar…
- 🔴 Announcement2026-09-29Kronox Lab Sciences announced the completion of its share sale to Indo Borax & Chemicals, reducing promoter holdings to 9.95% and appointing new direc…
- 🔴 Announcement2026-09-29Kronox Lab Sciences announced the completion of its share sale to Indo Borax & Chemicals, reducing promoter holdings to 9.95% and triggering a board r…
- 🟡 Board Meeting2026-09-29Kronox Lab Sciences announced on September 29, 2026, that the sale of 64.26% of its shares to Indo Borax & Chemicals Limited closed, leading to the re…
- 🔴 Announcement2026-09-29Kronox Lab Sciences announced the completion of a 64.26% share sale to Indo Borax & Chemicals, resulting in the Sellers exiting the promoter group. Th…
🧠 Analyst's Read
Kronox Lab Sciences is in a state of flux following a change of control, with financial performance remaining stable but future direction unclear. Investors should monitor the new management’s strategic initiatives, capital allocation plans, and potential disclosures on business segments or growth targets in upcoming filings to assess the company’s long-term viability under its new governance structure.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when KRONOX files new disclosures
Track KRONOX filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track KRONOX — FreeFree account · 2 AI queries/day